Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249834
Status:
COMPLETED
Last Update Posted:
2018-03-30
First Post:
2005-11-04
Brief Title:
Safety and Efficacy of Pre-defined Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization IVF
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Study Overview
Official Title:
A Phase IIIBIV Open Label Study to Assess the Efficacy and Safety of a Pre-defined Fixed Dose of Gonal-f Filled-by-Mass in a Prefilled Pen Based on Subject Baseline Characteristics for Ovarian Stimulation in Subjects Undergoing in Vitro Fertilization IVF
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONSORT
Brief Summary:
Clinical validation of the assisted reproductive technology ART treatment guidelines which determine the optimal dose of recombinant human follicle stimulating hormone r-hFSH based on subject baseline characteristicspredictors of ovarian response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None